


Welcome

z-Movi training presentation


Ray Wang | FAS CS

LUMICKS


LUMICKS



Technology



Cell-cell binding is governed by a complex and dynamic interplay between the multitude of **receptor-ligand binding** and **cell activity** in the context of the **physiological environment**






Cell Avidity measures cell-cell binding, a critical step in the Mechanism of Action

Key Steps of the Mechanism of Action



Molecular binding

Cell-Cell Binding


Biological outcome






Alternative tools:



Cell Avidity measures the *time-sensitive handshake* between cells



Alternative tools:



“Need for technology that allows direct, fast and high throughput measurements of T cell binding avidity.”

z-Movi[®] Cell Avidity Analyzer




z-Movi technology


z-Movi a complete benchtop solution using acoustic force technology in a chip

Let's zoom in!

Chip technology:



Fluorescence imaging is used to determine if T cells are bound or not to the tumor monolayer




Non tumor targeting T cells




Tumor targeting T cells

Acoustic Node




Easy to interpret avidity curves to rank order desired functional interactions




Avidity curves


Percentage of bound T cells as a function of force (negative control, NTD)



Bar graphs




Percentage effector cells that still bind to the monolayer at the end of the force ramp (after application of 1000pN)



Violin dot plots






Track the force-resistance of individual events, allowing insights into population-level distribution data

Different applications for cell avidity measurements



Avidity Governs Diverse Classes of Cell Interfaces

Cell interactions fall into distinct mechanistic classes




	1. Native adhesion	2. Immune Synapses	3. Multivalent driven Engagement	4. Fc-Mediated Immune Engagement	5. Nanoparticles & Viral delivery
examples	<i>Integrin-ICAM (or ECM)</i>	<i>TCR-pMHC</i>	<i>Receptor co-clustering (non-synaptic)</i>	<i>ADCC</i>	<i>LNP delivery</i>
	<i>aGPCRs</i>	<i>NK KIR-HLA</i>	<i>Biparatopic antibody induced clustering</i>	<i>ADCP</i>	<i>Viral infections</i>
	<i>CD44-HA</i>	<i>TCE/CAR synapse</i>	<i>Death receptor clustering</i>	<i>Complement engagement</i>	<i>Liposome – Cell</i>

Avidity changes reflect how biological or engineered perturbations alter these interactions:

Biological state & regulation	Therapeutic & engineered inputs
<ul style="list-style-type: none"> Genetic perturbations (KO, knock-in, expression level, mutations) Cell Metabolism & state (eg activated/exhausted/glycosylation) Signalling-driven receptor activation or redistribution 	<ul style="list-style-type: none"> Small molecules and biologics Engineered receptors or ligands (e.g. CARs, TCEs) Particles and delivery systems (e.g. antibodies, LNPs)



Limited options to measure CAR design changes on NK cells to enhance synaptic-binding



Problem

CAR-NK cell efficacy is limited by weak immune synapses and a *lack of rapid reproducible assays to assess design changes* that affect this important cell-cell interaction.

Hypothesis

Adding an intracellular PDZ domain to the CAR will *enhance NK synapse formation*, improving organization, strength, and tumor binding, *only measurable by cell avidity*.





Dr. Stephan Gottschalk

Endowed Chair in Bone Marrow Transplantation & Cellular Therapy
St. Jude Children's Research Hospital



Synapse-tuned CARs demonstrated enhanced cell avidity and anti-tumor activity in CAR-NK cells




Outcome

PDZ-modified CAR-NKs showed *enhanced immune synapse signaling*, increased cell avidity to solid tumors, and improved in vivo efficacy in mouse models.



Dr. Stephan Gottschalk

Endowed Chair in Bone Marrow Transplantation & Cellular Therapy
St. Jude Children's Research Hospital




Avidity-tuning for improved safety of CAR T therapy in solid tumors



Dr. Yufei Wang

Sr. Postdoctoral researcher
Dana Farber Cancer Institute




Hypothesis



Incorporating a lower-affinity scFv domain will allow sufficiently potent binding of tumor cells, while mitigating on-target off-tumor bindings.

Problem

Affinity measurements or in vitro cytotoxicity cannot predict on-target-off-tumor binding in a cellular context, which could lead to wrongful dismissal of ideal CAR T candidates, or it requires elaborate and extensive in vivo testing.




Avidity analysis demonstrates safe CAR-T binding to healthy cells



Outcome


G9 CAR-T product shows strong and potent binding to solid tumor cells, comparable to G250. In addition, as opposed to the clinically toxic G250, G9 anti-CAIX CAR-T demonstrates low and safe binding to healthy cells



Cell Avidity uncovers a critical binding mechanism impairing CAR-T potency in the TME



Dr. Marco Ruella
Associate Professor of Medicine
Hospital of the University of
Pennsylvania




Problem



A key mechanism deployed by the TME is the **upregulation of immune checkpoint molecules, which affect cell binding**. The BTLA-HVEM interaction between CAR-T cells and tumor cells has emerged as a critical factor in **T-cell inhibition and exhaustion**. Proving the mechanism of action is hard applying current technologies.

Hypothesis

Avidity enhancement can be achieved by deleting BTLA expression on CAR-T cells to improve synapse formation, expansion, cytokine secretion and potency *in vivo*.



Avidity enhancement by deleting BTLA improves CAR-T potency in the TME



Outcome


BTLA-deficient CAR-T cells exhibited increased cell avidity to tumor targets when using CD19-targeting CAR-T cells leading to **improved functionality *in vivo***




Cell Reports Medicine

Article

Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia



Cord Blood




MACS Isolation

Vehicle/Ven
18 h

Co-culture

NK cells
AML cells
(KG-1a, THP-1,
Primary AML cells)







Venetoclax (BCL-2 inhibitor) enhances NK cell cytotoxicity in AML patients




Venetoclax increases NK cell avidity for AML cells and improves IS formation via NF- κ B pathway

lytic granule polarization and IS formation was increased


Enhanced avidity of NK cells to AML cells by Venetoclax was suppressed by NK- κ B inhibitor SN50





Introducing multivalency upon Fc-domain inclusion restores cell avidity for CA9 on ccRCC

3.4 hours half-life 3.9 days
4.5 days



Problem

Current technologies lack the ability to fully characterize functional trade-offs between first- and second-generation bispecific T-cell engagers or do not allow the assessment of the impact of structural modifications, like the Fc domain in PBTE formats, on mechanism of action.




Dr. David Weiner

Executive Vice President & Director of Vaccine and Immunotherapy Center, Wistar Institute



Hypothesis

Adding an extra tumor-targeting (PMTE format) domain, thereby increasing cell avidity, restores the engager's function, creating a potent format with Fc-enhanced half-life.

BTE: bispecific T cell engager; PBTE: persistent BTE; PMTE: persistent multivalent TE



Format-tuning of CE by including an Fc-domain for increased half-life is only beneficial upon introducing multivalency for tumor-targeting




Outcome

PMTE's additional Ag binder restores PBTE's Fc-domain related reduced CA9 (target on ccRCC) avidity. The repercussions of the PBTE's parallel reductions in flow binding appeared to take shape with weaker synapses while the PMTE's higher avidity for CA9 lent itself to stronger synapses.



STARs and TCRs tend to form tighter immune synapses with target cells than CARs



Problem

CARs exhibit 10–100 times lower sensitivity than T cell receptors (TCRs) when targeting human leukocyte antigen (HLA) class I-presented p53R175H neoantigen


Hypothesis

Introduced T cell receptor fusion constructs (TRuCs) and synthetic TCRs and antigen receptors (STARs) can enhance CAR functionality




Dr. Xin Lin



School of Basic Medical Sciences
Tsinghua University



Protein-on-glass Avidity as a novel tool for mechanistic insights into ECM-cell interactions for metastasis



Dr. Lining (Arnold) Ju.
USYD, School of Biomedical Engineering



Problem

Current approaches to measure cancer cell-ECM interactions are either low throughput, not quantitative, or with poor sensitivity and reproducibility.


This makes it difficult to obtain robust data and uncover the MoA behind the metastatic potential of cancer cells.

Hypothesis

Cancer cell – ECM interactions directly correlates to the metastatic potential of cancer cells.

z-Movi Cell Avidity Analyzer

- z-Movi[®] Cell Avidity Analyzer
 - z-Movi Microscope
 - z-Movi Controller
 - 5x z-Movi Chips
 - Workstation (desktop, screen, mouse, keyboard, external SSD)
- Oceon[™] Avidity Software



z-Movi Instrument – Microscope



Specification overview

Number of cells analyzed	~400 cells*
Maximum force applicable on 10 µm polystyrene beads	Up to 1 nano-Newtons
Brightfield/fluorescence illumination	LED (670 nm)/(635 nm)
Objective/Magnification	10x/6.25x
Field of view	1 mm x 2 mm
Fluorescence detection bandwidth	660 – 750 nm
Brightfield/fluorescent frame rate	5 Hz
Dimensions - w x h x d	200 mm x 320 mm x 200 mm
Weight	7.0 kg

*typically 200-300 individual cells are analyzed

z-Movi Instrument – Controller box



- The controller box drives the microscope, and enables the communication between the z-Movi Microscope and the computer.
- Separation of controller and microscope electronics ensures the most stable functioning of the microscope.
- Power cables are equipped with the European plug

Specification overview

Dimensions - w x h x d	250 mm x 80 mm x 225 mm
Weight	2.6 kg

Chip glossary

Chip screws – 4x

- Four chip screws hold the chip together and closed

Tubing (outlet)

- Media/cells flow out



Manual fluidics control (valve adaptor)

- Flow control (open/closed)
- Zero flow

Inlet through transparent reservoir

Captive screw (thumb screws – 4x)

- Holds the chip in place when placed on the z-Movi



Valve

- Control the flow of the liquid from the reservoir to the flow cell



Valve adaptor

- Connects the white adapter for placing the syringe in the Luer lock adapter


Luer lock adapter in the valve

- Makes it possible to turn the syringe and having an airtight connection between the valve and the syringe

Chip glossary




z-Movi Chips



z-Movi Chip Warranty

- What is a run? An experimental force ramp that lasts over 10s.
- What is not a run? Monolayer testing: will use fixed forced.

Workflow




Avidity Experiment Workflow

- 1 Chip preparation (1hrs)**
Chip cleaned/1M NaOH Functionalization
Surface Coating
- 2 Chip seeding (2-3 hrs)**
Monolayers
- 3 Tracked cell staining (1hrs)**
- 4 Data Acquisition (1-3hrs)**
- 5 Data Analysis (10min- ∞)**

Simple workflow to measure binding avidity of multiple effectors on a single target monolayer



Method



1. Culture target monolayer

- Select target cells (could be a panel)
- Typically 100×10^6 cells/mL in max. 10-20uL are needed per chip.
- Seed chips to generate target cell monolayer (~3 hrs)


2. Prepare and flush in T cell populations

- Generate engineered T cell populations of interest
- Use fluorescent dye for T cell tracking
- $1-2 \times 10^5$ cells in ~10-20uL are needed per run
- Preparation time for avidity assay: ~1 hour

3-4. Co-culture target cells with T cells

- Incubate engineered T cells with target cells
- Start acoustic force ramp (2.5 min – 0-1000 pN)
- Wash away T cells and incubate next T cell population (n=5 runs)
- Perform avidity measurements: 5 runs ~ 1 hour

General workflow





Perform the runs in the following order:



- a. No antibody negative control (medium only)
- b. Irrelevant antibody negative control (optional)
- c. Experimental antibody

*Note: only 1 positive binding antibody can be run per chip



z-Movi cell avidity measurements as a quantitative systems pharmacology (QSP) model for cell engagers



5 min co-culture, n=2



5 min co-culture, n=3



10 min co-culture, n=1

Step 1

Adhere target cells

In z-Movi chip. Incubate for at least 2 hours




Material

chip cleaning	dH ₂ O
cell preparation	PBS
chip coating	Poly-L-lysine (for chip coating) [SigmaAldrich, P4707-50ML] ※
chip coating	Concanavalin A (Sigma-Aldrich, cat. #C2010-25MG) ※
cell staining	CellTrace™ Far Red dye (for staining effectors) [ThermoFischer, C34564] ※
cell preparation	TrypLE (gentle dissociation reagent) [ThermoFisher, 12604013]
cell preparation	HEPES (1M) [ThermoFischer, 15630106] , make 25mM in the medium
chip coating	1M NaOH (0.22 μm filtered)
cell preparation	Culture medium with/without FBS (no other added contents)
chip cleaning	Tween 20 (Sigma-Aldrich cat. # P9416-100ML)
chip cleaning	Bleach (5% w/v or containing 50g/L active chlorine)
chip cleaning	1-Ethyl-3-methylimidazolium dicyanamide (Thermo Fisher, catalog number: H26901.18; Sigma-Aldrich, catalog number: 713384)
※ Please order the same #Catlog reagents for PLL, ConA, Far Red dye and 1-Ethyl-3-methylimidazolium dicyanamide	

Day -2: Cell culture preparation


- 70 - 80% cell confluency in the flask at the day of in-chip cell seeding.
- Ensure for best cell quality (viability >95%)



Day -1 or Experiment Day: Chip preparation

Activate glass with NaOH 1M

- 10-minute incubation at RT
- Coat chips within 20 minutes after activation with NaOH!
- Never leave chips incubation longer than 1h maximum!



Coating reagent

- **Coat glass with Poly-L-Lysine**
 - Flush in PLL and incubate for 10 minutes (or Concanavalin A (1mg/mL or 5mg/mL))
 - Wash twice with PBS
 - Continue seeding OR: Dry chips and store until use (up to 3 days)
 - Rehydrate with PBS/media before in-chip seeding
- Con A is a plant lectin that binds to glycoproteins and glycolipids on the cell membrane.

Con A-coated chips can be prepared 0-1 day before monolayer seeding. If prepared in advance, Con A-coated chips should be stored **wet**, filled with 1X PBS at RT in the dark

Concanavalin A (Con A) ([Sigma-Aldrich, catalog number: C2010](#))

Stock: Con A dissolved in 1X PBS, at 5 mg/mL, frozen in 100 µL aliquots. Do not freeze/thaw more than once.

Working stock: Dilute 100 µL Con A stock solution to 1 mg/mL with 400 µL 1X PBS.

Experiment Day: NALM6

Tissue Culture Conditions for optimal monolayer preparation

Note. Cells are generally split 1 or two days prior to the experiment in the following ratios to obtain the recommended confluency or concentration.

Recommended confluency or cell concentration in 1 T75 culture flask on the day of the experiment:

1*10⁶/ml

Recommended splitting rate for 1 day prior to experiment: 0.4*10⁶/ml


Recommended splitting rate for 2 days prior to experiment: 0.3*10⁶/ml

Recommended splitting rate for 3 days (weekend) for culture maintenance: 0.2*10⁶/ml

Cells	NALM6
Medium	RPMI + 10% FCS + 25mM HEPES
Coating	PLL
Seeding concentration	180x10 ⁶ /ml
Time and conditions after seeding	30 min in serum free medium
Time and conditions after medium exchange	1.5 hours in 10% medium


Experiment Day: Bad vs. Good Monolayer

Low confluency




< 50% confluency

Minimum threshold



80% confluency


Optimal



>90% confluency


Experiment Day: Bad vs. Good Monolayer

Bad




< 50% confluency

Minimum Threshold



80% confluency

Optimal



>90% confluency

Target monolayer: considerations for successful monolayer

- A. **Pre-seeding cell culture**- cell viability, cell confluence in the flask
- B. **Chip cleaning**- chips must be cleaned on the same day and incubation with chemicals
- C. **Glass coating**- even coating using PLL (bubble-free), alternative coating methods if necessary
- D. **Cell density**- optimized monolayer concentration based on cell size and clumpiness
- E. **Cell adherence time**- 1hr is ultimate incubation time goal, however, it is cell line-dependent
- F. **Monolayer state in the chip**- overall monolayer “happiness” in the chip varies depending on cell line. Usually, monolayer is usable 2-4 hours post seeding to assure reproducible data chip-to-chip

Step 2

Flush your tracked cells



Experiment Day: Tracked cell staining

1. Prepare 200,000 tracked cells in 20uL per chip (10×10^6 cells/mL suspension).
2. Wash with PBS.
3. Add 1 μ L of stock CellTrace™ Far Red Dye to cell pellet (1uL of stock dye to 1mL 1X PBS).
4. Incubate for 15 mins in the dark at 37°C.
5. Add 5X volume of complete media to cells and mix well by pipetting.
6. Incubate at 37°C for 5 mins
7. Wash 1X with complete medium.
8. Resuspend stained cells in complete medium at 10×10^6 cells/mL.



Experiment Day: Determine good staining and concentration of effector cells


Good



Sparse



Dim cells



Optimal concentration is about 250-500 cells in FOV

Step 3


Incubation

5 minutes




Find best incubation time: best window

Avidity Curve



Avidity Comparison



Step 4

Acoustic force


To lift off the tracked effector cells from the target cells. 2.5 minutes




Step 5

Sit back and watch

your avidity measurement results in real-time



Chip top view



Repeat Steps 2-5

Flush in tracked effector cells+ CEs

Repeat with new tracked effector cell population


Perform the runs in the following order:

a.No antibody negative control (medium only)


b.Irrelevant antibody negative control

c.Experimental antibody

*Note: only 1 positive binding antibody can be run per chip



Day 0: Cleaning chips



Make sure the flow chamber is bubble free during every incubation step

VERY important step. Dirty chips will affect monolayer adherence and introduce more bubbles. Do not rush this!!!


1 cleaning protocol


Step	Chemical	Why
1	H2O	To rinse of any cell media
2	Bleach 5% (10min-30min)	to kill the cells, it always must be done the same day after the experiment
3	H2O	To rinse Bleach
4	Ionic Liquid (30min~3days)	To remove coating/debris from flow channel
5	2% Tween 20	To get rid of the IL (doesn't dissolve in H2O) residues
6	H2O	To rinse off all soap residues
7	Coating or Drying	Coating immediately after, or dry for longer storage
7	1M NaOH (1h)	Etching of glass, getting rid of a top layer making the O- groups on glass functional
8	H2O	Rinse NaOH residues and keep glass functional
9	Coating	Coating PLL/ConA

Data analysis

Oceon: Analyze your avidity measurements

Good afternoon ☀️



 **Analyze**

Analyze and finetune your measurements. Once everything looks top-notch you can export your results for further statistical analysis and presentation.

Start analyzing

Data merger



*No need of license for data analysis software





Effector Cells

Target Cells

Before Ramp



After Ramp



Data files: Single-cell analysis and avidity curve

Single-cell

9	Total number of selected cells	152	
10	Cells included in avidity curve	114	
11	Monolayer confluency (%)	76	
12	Regular cell count	100	
13	Glass cell count	28	
14	Hinge cell count	14	
15	Covered cell count	10	
16	Regular class	included	
17	Leftover class	excluded	
18	Glass class	excluded	
19	Hinge class (included / treat as bound)	included	treat as bound
20	Covered class	excluded	
21	Custom 1 class (included / treat as bound)	included	
22	Custom 2 class (included / treat as bound)	included	
23	Custom 3 class (included / treat as bound)	included	
24	Custom 4 class (included / treat as bound)	included	
25	Avidity plateau (%)	14.03509	
26	---		
27			
28	Index	Time (s)	Force (pN)
29		0	6 40
30		1	2.4 16
31		2	3.2 21.33333
32		3	6 40
33		4	8.8 58.66667
34		5	bound bound
35		6	bound bound
36		8	2.2 14.66667
37		9	37.4 249.3333
38		11	4.4 29.33333
39		12	2.8 18.66667

Avidity Curve

9	Total number of selected cells	152	
10	Cells included in avidity curve	114	
11	Monolayer confluency (%)	76	
12	Regular cell count	100	
13	Glass cell count	28	
14	Hinge cell count	14	
15	Covered cell count	10	
16	Regular class	included	
17	Leftover class	excluded	
18	Glass class	excluded	
19	Hinge class (included / treat as bound)	included	treat as bound
20	Covered class	excluded	
21	Custom 1 class (included / treat as bound)	included	
22	Custom 2 class (included / treat as bound)	included	
23	Custom 3 class (included / treat as bound)	included	
24	Custom 4 class (included / treat as bound)	included	
25	Avidity plateau (%)	14.03508772	
26	---		
27			
28	Force (pN)	Bound cells (%)	
29		0	100
30		1.333333333	100
31		2.666666667	100
32		4	100
33		5.333333333	100
34		6.666666667	100
35		8	100
36		9.333333333	100

<https://help-zmovi.lumicks.com/>

Password: iloveavidity

Monolayer